NEW YORK (GenomeWeb News) – Regulus Therapeutics, a developer of microRNA-based therapeutics, announced after the close of the market Wednesday that it has signed a deal with Biogen Idec to identify blood-borne miRNA biomarkers for multiple sclerosis.

In exchange for its miRNA know how, Regulus will receive undisclosed upfront and milestone payments. Biogen Idec will also make an undisclosed investment in Regulus, which was formed in 2007 as a joint venture between RNAi firm Alnylam Pharmaceuticals and antisense drug developer Isis Pharmaceuticals.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

York University researchers find genomic evidence of inbreeding in the yellow-banded bumblebee, according to Reuters.

In its survey of US adults, the Pew Research Center finds that views on the genetic engineering of animals depend on why it's done.

The Scientist reports agricultural researchers are working on a gene-stacking tool.

In Nature this week: statistical method for overcoming case-control imbalance issues, and more.